Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

FDA Approves Exact Sciences’ colon screening test

 (Image source: nytimes.com)

Shares of the diagnostic medical research firm EXACT Sciences Corporation (NASDAQ:EXAS) are advancing this morning on news that the FDA’s advisory committee unanimously approved its screening test for colon cancer called Cologuard. Cologuard is less invasive than the traditional colonoscopy test. In addition, Cologuard can detect early signs of cancer at successful rates according to a study conducted by the New England Journal of Medicine. According to the study conducted by New England Journal of Medicine, Cologuard had a cancer detection rate of 92 percent on 13,000 subjects. Cologuard only requires patients to submit a stool sample to detect for colorectal cancer. Colon cancer is one of the leading cancers in the U.S.